Evaluation of VagiVitalAC for Treatment of Candida Vulvovaginitis

Status Recruiting

Clinical Trial Summary

Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candidiasis in the vagina is commonly called a "vaginal yeast infection." Another names for this infection is "vaginal candidiasis". The symptoms of vaginal candidiasis include: Vaginal itching or soreness, Pain during sexual intercourse, Pain or discomfort when urinating and Abnormal vaginal discharge. VagiVitalAC is a modified version of the existing gel VagiVital, formulated to act as a treatment for fungal infections. This clinical investigation is a two-part study consisting of a pilot part followed by a randomized part. The aim of the pilot part is to evaluate if VagiVitalAC is able to cure the vulvovaginal candidiasis in at least 70% of the patients after 7 days treatment. If the proportion of cured patients is at least 70 %, the next part, the randomized part, will be performed. In the randomized part, the treatment efficacy and safety of VagiVitalAC on candida vulvovaginitis will be evaluated by comparing a treatment group with a control group receiving no treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05012852
Study type	Interventional
Source	PepTonic Medical AB
Contact	Dan Markusson
Phone	+46104750800
Email	registrator@etikprovning.se
Status	Recruiting
Phase	N/A
Start date	September 2021
Completion date	June 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02150655` - Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women	Phase 0
Completed	`NCT00755053` - Comparative Efficacy of Ovule vs Tablet	Phase 3
Completed	`NCT02679456` - Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis	Phase 2
Completed	`NCT02242695` - Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis	Phase 4
Recruiting	`NCT06397248` - DeVEnIR: Defining Vulvovaginal Candidiasis - Elements of Infection and Remedy
Completed	`NCT00895453` - Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)	N/A
Completed	`NCT05327192` - VVC Sampling Study for Analysis Validation
Completed	`NCT05399641` - Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis	Phase 3
Completed	`NCT01806623` - The Study Of Fluconazole For Vulvovaginal Candidiasis	Phase 3
Recruiting	`NCT05079711` - Comparative Performance of a Vaginal Yeast Test
Completed	`NCT05507333` - Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis	N/A
Completed	`NCT01144286` - Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment	Phase 2
Completed	`NCT00353561` - Diabetes Mellitus and Vulvovaginal Candidiasis	Phase 3
Recruiting	`NCT05895162` - Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis.	N/A
Not yet recruiting	`NCT06450990` - Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection	Phase 1/Phase 2
Recruiting	`NCT05908682` - Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
Completed	`NCT02203942` - Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis	N/A
Completed	`NCT01926028` - Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis	Phase 1/Phase 2
Completed	`NCT00194324` - Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina	Phase 4
Completed	`NCT02866227` - TOL-463 Phase 2 Study for Vaginitis	Phase 2